Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Zr-based MOF NPs for cryopreservation of cells including, for example, red blood cells.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: A combined remediation method of petroleum-contaminated soil includes: impurity removal pretreatment, photocatalytic pre-oxidation, stepwise thermal desorption of petroleum from soil, and high-temperature oxidation; with iron-titanium composite metal oxide (ITCMO) as a catalyst, conducting oxidation pretreatment under light conditions so that some cross-linked structures in macromolecular petroleum contaminants are broken and degraded; and conducting stepwise pyrolysis to achieve a removal rate of more than 98.00%. The new method adopts a combined remediation technology of photocatalytic pre-oxidation-stepwise pyrolysis, which realizes a relatively-high removal rate of petroleum hydrocarbons and the efficient and harmless remediation of high-concentration petroleum-contaminated soil, and remedied soil can be reused.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: A data dividing method applied to a computing device that performs a convolution operation based on an input image data and a weight data is provided. The method includes: determining a restriction condition in connection with the performing of the convolution operation by the computing device; determining a set of candidate data blocks for the input image data and a set of candidate data blocks for the weight data according to the restriction condition; generating an evaluation result by evaluating, according to candidate data blocks in the set of candidate data blocks for the input image data and the set of candidate data blocks for the weight data, an amount of data load of the computing device in accessing both an external memory and an internal memory of the computing device; and determining a method of dividing the input image data and the weight data according to the evaluation result.

Abstract: A multiplier includes a multiplier preprocessing circuit, an encoding code, an addition circuit and a partial product selection circuit. The multiplier preprocessing circuit generates different input coding values from a received multiplier according to different operation bit widths. The encoding circuit generates different coded values according to different input coding values, and performs an operation according to different coded values and a received multiplicand to obtain a first partial product. The addition circuit accumulates the first partial product for a corresponding number of times according to different operation bit widths to generate different second partial products. The multiplier supports multiplication of multiple mixed bit widths, and a multiplier unit can be repeatedly used for multiplication operations in encounters with different precisions.

Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Methods, systems, and software are provided for validating a somatic sequence variant in a subject having a cancer condition. Sequence reads are obtained from sequencing cell-free DNA fragments in a liquid biopsy sample of the subject. Sequence reads are aligned to a reference sequence. A variant allele fragment count and locus fragment count are identified for a candidate variant that maps to a locus in the reference sequence. The variant allele fragment count is compared against a dynamic variant count threshold for the locus. The threshold is based on a pre-test odds of a positive variant call for the locus, based on the prevalence of variants in a genomic region including the locus in a cohort of subjects having the cancer condition. The somatic sequence variant in the subject is validated, or rejected, when the variant allele fragment count for the candidate variant satisfies, or does not satisfy, the threshold.

Abstract: The present invention relates to an R-T-B sintered magnet and a preparation method thereof. The sintered magnet includes a grain boundary region T1, a shell layer region T2 and an R2Fe14B grain region T3; at 10 ?m to 60 ?m from a surface of the sintered magnet toward a center thereof, an area ratio of the shell layer region T2 to the R2Fe14B grain region T3 is 0.1 to 0.3, and a thickness of the shell layer region T2 is 0.5 ?m to 1.2 ?m; and an average coating percent of the shell layer region T2 on the R2Fe14B grain region T3 is 80% or more. In the present invention, by optimizing a preparation process and a microstructure of a traditional rare earth permanent magnet, diffusion efficiency of heavy rare earth in the magnet is improved, such that coercivity of the magnet is greatly improved, and manufacturing cost is reduced.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as antagonist of TLR7 and/or TLR8 and/or TLR9 in the treatment of autoimmune diseases as well as auto-inflammation diseases.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: An electronic cigarette control method is provided, including: S1, obtaining a resistance value of a heating element when a starting unit is triggered for the first time by a resistance detection unit, storing the resistance value as an initial resistance value; S2, obtaining a target temperature of the heating element, to obtain a target resistance value according to the initial resistance value; S3, obtaining a first real-time resistance value corresponding to a first preset time of each trigger, to calculate a resistance value change in the first preset time, confirming whether the resistance value change is larger than a first preset value; if yes, turning off an input power of the heating element; if no, executing step S4; S4, obtaining a real-time resistance value according to a preset rule through the resistance detection unit, to control the input power to ensure the real-time resistance value is the target resistance value.

Abstract: An electrical arrangement (1), comprising a housing (2) having a housing opening (20), an electrical component (3) within the housing (20), a power supply connection (4), a contact protection cover (5), and a circuit breaker (6) which can be inserted into the housing (2), wherein, in the inserted state, the circuit breaker (6) connects the electrical component (3) to the power supply connection (4) and, in the withdrawn state, the circuit breaker (6) disconnects the connection, wherein the contact protection cover (5) can be fastened to the housing (2) in a locking position in which the contact protection cover (5) covers the housing opening (20), and wherein, in the inserted state, the circuit breaker (6) locks the contact protection cover (5) in the locking position.

Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Systems and methods for models utilizing siloed data are disclosed. For example, data stored with and/or available to one or more systems may be siloed such that it may not be aggregated and/or shared with other systems. The presently-disclosed systems and methods utilize predictive layers and models to allow each system to predict outcomes using its own data and then models are shared between systems to allow each associated system to gain the benefits of the data of other systems without aggregating such data or otherwise sharing the data.

Abstract: The present invention relates to a compound of formula (I) wherein R4 is C1-6alkyl, halogen or cyano; R5 is halogen; R2 is 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridinyl which is unsubstituted or substituted by C1-6alkyl or haloC1-6alkyl; 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridinyl which is unsubstituted or substituted one or two times by C1-6alkyl; or 5,6-dihydro-4H-pyrrolo[3,4-c]pyrazolyl; R3 is C1-6alkyl; L is azetidinyl or piperidinyl; or a pharmaceutically acceptable salt thereof, for use as a TLR7, TLR8 and/or TLR9 antagonist for the treatment or prophylaxis of autoimmune diseases, such as e.g. systemic lupus erythematosus or lupus nephritis.